In human gastric cancer, a previous study reported that HB-EGF immunoreactivity was detected in 61 to 72 % of cancer cells and was generally stronger in deeply invasive cancer cells than in cancer cells of more superficial layers [20,21]. The gene discussed is HBEGF; the disease is cancer.